|
| Press Releases |
|
 |
|
| Thursday, June 29, 2023 |
|
|
NanoViricides Announces that Clinical Trials of Its Broad-Spectrum Antiviral Drug NV-CoV-2 Have Begun |
| NanoViricides, Inc. (NYSE American:NNVC) (the "Company") reports that clinical trials of its broad-spectrum antiviral drug NV-CoV-2 began on June 17, 2023 with two oral drug products: (i) NV-CoV-2 Oral Syrup, and (ii) NV-CoV-2 Oral Gummies. more info >> |
|
|
NanoViricides Announces that Clinical Trials of Its Broad-Spectrum Antiviral Drug NV-CoV-2 Have Begun |
| NanoViricides, Inc. (NYSE American:NNVC) (the "Company") reports that clinical trials of its broad-spectrum antiviral drug NV-CoV-2 began on June 17, 2023 with two oral drug products: (i) NV-CoV-2 Oral Syrup, and (ii) NV-CoV-2 Oral Gummies. more info >> |
|
| Wednesday, September 16, 2020 |
|
|
NanoViricides Nominates a Novel Candidate for Advancing Into Clinical Trials for Treatment of COVID-19 |
| NanoViricides, Inc. (NYSE American:NNVC) (the "Company") a global leader in the development of highly effective antiviral therapies based on a novel nanomedicines platform, today announced that it has nominated a clinical drug candidate for the treatment of COVID-19, thus further advancing its COVID-19 program closer to human clinical trials. more info >> |
|
| Wednesday, May 20, 2020 |
|
|
Strong Effectiveness of NanoViricides Drug Candidates Observed in an Animal Model of Infection by an ACE2-using Human Coronavirus |
| NanoViricides, Inc. (NYSE American: NNVC) (the "Company") a leader in the development of highly effective antiviral therapies based on a novel nanomedicines platform, announced today that strong effectiveness against infection by an ACE2-utilizing coronavirus in an animal model has been observed for the drug candidates it is developing against SARS-CoV-2 to treat COVID-19 spectrum of diseases. more info >> |
|
|
Strong Effectiveness of NanoViricides Drug Candidates Observed in an Animal Model of Infection by an ACE2-using Human Coronavirus |
| NanoViricides, Inc. (NYSE American: NNVC) (the "Company") a leader in the development of highly effective antiviral therapies based on a novel nanomedicines platform, announced today that strong effectiveness against infection by an ACE2-utilizing coronavirus in an animal model has been observed for the drug candidates it is developing against SARS-CoV-2 to treat COVID-19 spectrum of diseases. more info >> |
|
| Monday, March 16, 2020 |
|
|
Coronavirus Drug Development Update from NanoViricides, Inc. |
| NanoViricides, Inc. (NYSE American: NNVC) (the "Company") a leader in the development of highly effective antiviral therapies based on a novel nanomedicines platform, is providing an update on its efforts towards drug development for the current novel coronavirus SARS-CoV-2 that causes COVID-19. more info >> |
|
| Tuesday, March 17, 2020 |
|
|
NanoViricides社、新型コロナウイルス治療薬開発に関する最新情報を発表 |
| 新たなナノ医療プラットフォームを基盤に非常に効果的な抗ウイルス療法の開発でリードするNanoViricides社（NYSE American: NNVC） （以下「当社」）は、COVID-19を引き起こす現在の新型コロナウイルス（SARS-CoV-2）の治療薬開発に向けた取り組みについて最新情報を提供しています。 more info >> |
|
|
NanoViricides公司冠狀病毒藥物開發更新 |
| NanoViricides公司（美國紐約證券交易所交易代碼NNVC）（公司）是基於新型納米藥學平台（公司）開發高效抗病毒治療方法的領先公司，目前正在為造成COVID-19的當前新型冠狀病毒SARS-CoV-2進行藥物開發，現提供其工作相關更新。 more info >> |
|
|
NanoViricides公司冠状病毒药物开发更新 |
| NanoViricides公司（美国纽约证券交易所交易代码 NNVC）（公司）是基于新型纳米药学平台（公司）开发高效抗病毒治疗方法的领先公司，目前正在为造成COVID-19的当前新型冠状病毒SARS-CoV-2进行药物开发，现提供其工作相关更新。 more info >> |
|
| Monday, March 16, 2020 |
|
|
Coronavirus Drug Development Update from NanoViricides, Inc. |
| NanoViricides, Inc. (NYSE American: NNVC) (the "Company") a leader in the development of highly effective antiviral therapies based on a novel nanomedicines platform, is providing an update on its efforts towards drug development for the current novel coronavirus SARS-CoV-2 that causes COVID-19. more info >> |
|
|
|
|
|
|
|
|
|
| Latest Press Releases |
|
Anytime Fitness Accelerates Asia-Pacific Expansion
May 12, 2026 22:56 HKT/SGT
|
|
|
Redington MD and Group CEO V.S. Hariharan Appointed to GTDC Executive Committee
May 12, 2026 21:00 HKT/SGT
|
|
|
GMG Leases New Site for Production & Office Expansion
May 12, 2026 20:29 HKT/SGT
|
|
|
CANEX and Gold Basin Resources Announce Arrangement Agreement to Facilitate CANEX'S Acquisition of Remaining Gold Basin Shares
May 12, 2026 19:30 HKT/SGT
|
|
|
GIC進一步增持歌禮製藥-B（1672.HK）超1千萬股 持股比例升至7.00% 彰顯長期發展信心
May 12, 2026 19:12 HKT/SGT
|
|
|
GIC进一步增持歌礼制药-B（1672.HK）超1千万股 持股比例升至7.00% 彰显长期发展信心
May 12, 2026 19:12 HKT/SGT
|
|
|
SPARX Group Establishes "Mirai Creation Fund IV" Toyota Motor Corporation, Sumitomo Mitsui Banking Corporation, MUFG Bank, Ltd. and Mizuho Bank, Ltd. to Provide Capital Targeting Total Commitments of JPY100 billion
May 12, 2026 19:29 JST
|
|
|
GTJAI Assists State Bank of Mongolia in Completing a US$100 Million Reg S Bond Tap Issuance
May 12, 2026 17:45 HKT/SGT
|
|
|
國泰君安國際協助蒙古國家銀行完成1億美元Reg S債券增發
May 12, 2026 17:45 HKT/SGT
|
|
|
国泰君安国际协助蒙古国家银行完成1亿美元Reg S债券增发
May 12, 2026 17:45 HKT/SGT
|
|
|
Casa Minerals Inc. Receives Proceeds of $432,777 from Warrant Exercises
May 12, 2026 17:29 HKT/SGT
|
|
|
Anytime Fitness加速亞太擴張
May 12, 2026 17:14 HKT/SGT
|
|
|
Anytime Fitness加速亚太扩张
May 12, 2026 17:14 HKT/SGT
|
|
|
CleverTap และ Rabbit Rewards คว้ารางวัล Silver จากเวที Thailand MarTech Awards 2026 ตอกย้ำความสำเร็จด้าน Real-time, Agentic Customer Engagement
May 12, 2026 15:00 HKT/SGT
|
|
|
CleverTap and Rabbit Rewards win Silver at Thailand MarTech Awards 2026 for real-time, agentic customer engagement
May 12, 2026 15:00 HKT/SGT
|
|
|
|
|
More News >> |
|
|
|
|
|
